Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 3,872 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: FAST Clear all

Conditions: Healthy
Interventions: Metformin HCl 500 mg tablets, single dose, CLUCOPHAGE® XR 500 mg tablets, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Leptin administration, Fasting; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2003
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Healthy
Interventions: ARAVA® 20 mg tablets, Leflunomide 20 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 2
States / cities: Saint Charles, Missouri • Houston, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: HOE901-U300 (Insulin glargine new formulation), Lantus (Insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 82
States / cities: Chandler, Arizona • Little Rock, Arkansas • Bell Gardens, California + 71 more

Conditions: Metabolic Syndrome
Interventions: 3-V Bioscience-2640; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 35 Years to 60 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Hearing Loss, Sensorineural
Interventions: Hearing aid; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Small Bowel Obstruction, Gastrointestinal Hemorrhage
Interventions: RightSpot pH Indicator, Chest radiograph; Device · Radiation
Lead sponsor: RightBio Metrics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fibromyalgia
Interventions: Paced Auditory Serial Addition task (PASAT); Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Dementia, Telemedicine, Cognitive Dysfunction
Interventions: Not listed
Lead sponsor: Theodore Malmstrom, PhD; Other
Eligibility: 18 Years to 90 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bile Duct Cancer, Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct
Interventions: Cabozantinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Infectious Diseases
Interventions: Chagas Detect Plus; Other
Lead sponsor: InBios International, Inc.; Industry
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC; Drug
Lead sponsor: Actelion; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteers
Interventions: ZM-H1505R; Drug
Lead sponsor: Shanghai Zhimeng Biopharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Opioid-use Disorder, Cocaine Use Disorder
Interventions: Cariprazine 1.5 MG, Placebo; Drug
Lead sponsor: Kyle Kampman; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Participants
Interventions: LY2940680 Capsule(s) (Reference), LY2940680 Tablet (Test), Lansoprazole, Placebo Capsule(s); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Kidney Disease
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Staphylococcus Aureus, Staphylococcal Skin Infections, Bacteremia
Interventions: Not listed
Lead sponsor: Michael E. DeBakey VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Epic-Based Clinician Notification, Usual Care; Other
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Plano, Texas

Conditions: Nocturia
Interventions: desmopressin acetate, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 70
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more

Conditions: Pain
Interventions: Codeine Sulfate; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: ceritinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 7
States / cities: Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more

Conditions: Obstructive Sleep Apnea
Interventions: AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test; Drug · Diagnostic Test
Lead sponsor: Apnimed; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more

Conditions: Child Disruptive Behavior Disorders, Parent Child Relationship, Parent Management Training, Peer Support, Child Behavior Problems, Challenging Behavior, Positive Parenting
Interventions: FAST-B PEERS, FAST-B (First Approach Skills Training - Behavior); Behavioral
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: Not listed
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

A Relative Bioavailability Study of Metformin HCl 500 mg ER Tablets Under Non-fasting Conditions

Secondary Analysis of Gut Hormones and Inflammatory Cytokines in Fasting Subjects

Leflunomide 20 mg Tablets, Non-Fasting

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome

Hearing Aid Processing and Working Memory in Realistic Spatial Conditions

Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity

Generalized Hypersensitivity in Patients With Fibromyalgia Syndrome

EpxCogScreen -- A Phone-based Rapid Cognitive Screen (RCS)

Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma

Specificity Study of Diagnostic for Chagas Disease

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Doses in Healthy Participants

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

A Study of LY2940680 in Healthy Participants

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Rapid Test to Detect Staphylococcus Aureus in Blood and Wound Infections

RAndomized EHR-based Prescribing to Improve Disease-modifying Therapies for Cardio-Kidney-Metabolic Care (RAPID-CKM)

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Dose Linearity Study of Codeine Sulfate Under Fasted Conditions

The Efficacy of Doxazosin for Cocaine Users

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Crossover Trial of AD109 in Obstructive Sleep Apnea

Examining the Feasibility, Acceptability, and Fidelity of Utilizing Parent Training Graduates as Peer Supports